Vactech Oy
19.2.2024

The results of the PRV-101 vaccine Phase I trial published in Diabetologia.

Safety, tolerability and immunogenicity of PRV-101, a multivalent vaccine targeting coxsackie B viruses (CVBs) associated with type 1 diabetes: a double-blind randomised placebo-controlled Phase I trial

Read article (external site)

Previous

Vactech announces positive final results from First-In-Human study of Coxsackievirus B Vaccine Candidate PRV-101

Next

Vactech Appoints Dr. Tero Välimaa as New Chief Executive Officer

Career Opportunities

At Vactech, Innovation Meets Impact.
Join Us in Reshaping Global Health.

Join our team

 

 

About Vactech

Vactech is a company with a pipeline of product candidates focused on type 1 diabetes, celiac disease, and diagnostics. The primary focus of our research and product development is to unravel and treat the complexities of immune-mediated diseases and enteroviruses.

Read more
Latest News and Press Releases

New Insights into the Role of Enteroviruses in Type 1 Diabetes

Vactech Appoints Dr. Tero Välimaa as New Chief Executive Officer

The results of the PRV-101 vaccine Phase I trial published in Diabetologia.

Read all
Contact Us

Vactech Oy
Biokatu 8
33520 Tampere, Finland

Privacy Policy